Cargando…

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report

Thymic carcinoma is a rare neoplasm with a poor outcome due to its aggressive characteristics. For patients who are not operable, radiation therapy and/or palliative chemotherapy are indicated. However, no optimal chemotherapy regimen has been established. The present study reports the case of a 22-...

Descripción completa

Detalles Bibliográficos
Autores principales:	SHIMA, HIROSHI, OZASA, HIROAKI, TSUJI, TAKAHIRO, AJIMIZU, HITOMI, NOMIZO, TAKASHI, YAGI, YOSHITAKA, SAKAMORI, YUICHI, NAGAI, HIROKI, MINAMIGUCHI, SACHIKO, KIM, YOUNG HAK, MISHIMA, MICHIAKI
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4840747/ https://www.ncbi.nlm.nih.gov/pubmed/27123268 http://dx.doi.org/10.3892/mco.2016.803

Ejemplares similares

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma
por: Tsuji, Takahiro, et al.
Publicado: (2015)

Carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of thymic carcinoma
por: Takahashi, Akiko, et al.
Publicado: (2022)

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer
por: Tsuji, Takahiro, et al.
Publicado: (2017)

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
por: Nomizo, Takashi, et al.
Publicado: (2017)

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)

Repetitive responses to nanoparticle albumin‐bound paclitaxel and carboplatin in malignant pleural mesothelioma
por: Kanai, Osamu, et al.
Publicado: (2016)

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer
por: Ogimoto, Tatsuya, et al.
Publicado: (2023)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014)

Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
por: Ajimizu, Hitomi, et al.
Publicado: (2021)

Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
por: Ajimizu, Hitomi, et al.
Publicado: (2023)

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation
por: Tsuji, Takahiro, et al.
Publicado: (2020)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
por: Kuriyama, Yuka, et al.
Publicado: (2013)

Combination Therapy of Albumin-Bound Paclitaxel and Carboplatin as First Line Therapy in a Patient with Ovarian Cancer
por: Srinivasan, K. N, et al.
Publicado: (2014)

Efficacy evaluation of albumin-bound paclitaxel combined with carboplatin as neoadjuvant chemotherapy for primary epithelial ovarian cancer
por: Wang, Huan, et al.
Publicado: (2022)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab−Paclitaxel and Maintenance Monotherapy with nab−Paclitaxel: Two Case Reports
por: Araya, Tomoyuki, et al.
Publicado: (2020)

Total thymectomy for thymic lymphoepithelioma-like carcinoma—report of two cases
por: Kawagishi, Sachi, et al.
Publicado: (2019)

Successful multimodal treatment of stage IV lymphoepithelioma-like thymic carcinoma
por: Zielińska, Dominika, et al.
Publicado: (2022)

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab
por: Funazo, Tomoko Yamamoto, et al.
Publicado: (2019)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Funaishi, Kunihiko, et al.
Publicado: (2017)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

First-line albumin-bound paclitaxel/carboplatin plus apatinib in advanced pulmonary sarcomatoid carcinoma: A case series and review of the literature
por: Kong, Feng-Wei, et al.
Publicado: (2020)

Detection of Epstein‐Barr Virus DNA in a Japanese Case of Lymphoepithelioma‐like Thymic Carcinoma
por: Matsuno, Yoshihiro, et al.
Publicado: (1992)

Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1‐rearranged lung cancer
por: Yamazoe, Masatoshi, et al.
Publicado: (2022)

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022)

Ischemic Colitis Associated with Paclitaxel and Carboplatin Combination
por: Elsayed, Ahmed Gamal, et al.
Publicado: (2017)

Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis
por: Oda, Naohiro, et al.
Publicado: (2021)

Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan
por: Harano, Kenichi, et al.
Publicado: (2014)

Clinical outcome of thymic lymphoepithelioma-like carcinoma: Case report of a 14-year-old male
por: SEKIHARA, KUNIKO, et al.
Publicado: (2014)

Superior Therapeutic Efficacy of Nanoparticle Albumin Bound Paclitaxel Over Cremophor-Bound Paclitaxel in Experimental Esophageal Adenocarcinoma
por: Hassan, Md Sazzad, et al.
Publicado: (2018)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

Continuous morphine infusion for end-stage lung cancer patients
por: KIM, YOUNG HAK, et al.
Publicado: (2013)

Albumin-Bound Paclitaxel: Worthy of Further Study in Sarcomas
por: Tian, Zhichao, et al.
Publicado: (2022)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Successful Chemotherapy with Carboplatin and S-1 for Thymic Carcinoma: A Case Report
por: Igawa, Satoshi, et al.
Publicado: (2013)

The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study
por: Jiang, Wenjuan, et al.
Publicado: (2022)

Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration
por: Chen, Nianhang, et al.
Publicado: (2015)

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel
por: Jilaveanu, Lucia B., et al.
Publicado: (2013)

CARBOPLATIN-PACLITAXEL INDUCED ACUTE MULTI-VESSEL CORONARY THROMBOSIS
por: Fanous, Hanna, et al.
Publicado: (2022)

SPARC is a possible predictive marker for albumin-bound paclitaxel in non-small-cell lung cancer
por: Komiya, Kazutoshi, et al.
Publicado: (2016)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ombdsh3jalbjo22ooj1eq4hqmn